- Apex Biotechnology
-
PerformanceThe company's stock price closed at NT$31.2 on the TSE on Thursday, April 19, 2018.The company has reported consolidated revenues of NT$147 million for March 2018, representing a 6.5% drop on month and 16% drop on year.For the fourth quarter of 2017, the company totaled NT$472 million in consolidated revenues, down 1.3% sequentially and up 27.9% on year.Brief
Full name: Apex Biotechnology
Chinese name: 五鼎生物技術股份有限公司
Short name: Apex
Stock code: 1733
Tax ID: 16130182
Market: TSE
Established: 2 Dec 1997
Paid in capital: NT$997.27 million
Listed on TSE: 17 Sep 2001
Website: www.apexbio.com
-
Related news
- PCB maker Apex sees earnings up in 2Q16
- PCB maker Apex reports increased sales for May
- PCB firm Apex reports increased April revenues
- PCB maker Apex sees revenues up on month in January
- PCB maker Apex reports strong earnings for 2015
- PCB supplier Apex sees profits surge in 3Q15
- PCB maker Apex grows sales generated from auto sector
- PCB maker Apex sees new plant break even
-
Latest stock
Apex [1733] historical stock price (NT$) Date Volume (k) Transactions Value Open High Low Close Change Ask Bid 20-Apr 542 383 16,893,600 31.45 31.45 30.85 31.20 +0.00 +0.00% 31.10 31.20 19-Apr 499 312 15,691,200 31.70 31.75 31.20 31.20 +0.00 +0.00% 31.20 31.45 18-Apr 461 275 14,406,950 31.60 31.80 31.05 31.20 -0.25 -0.79% 31.20 31.30 17-Apr 780 508 24,540,100 32.00 32.10 31.10 31.45 -0.45 -1.41% 31.40 31.45 16-Apr 1,067 747 34,468,800 32.50 33.00 31.80 31.90 +0.30 +0.95% 31.90 32.00 13-Apr 755 459 24,035,750 32.20 32.50 31.40 31.60 -0.60 -1.86% 31.60 31.70 - Source: TSE, compiled by Digitimes
Latest salesApex: Consolidated revenues, Mar 2017 - Mar 2018 (NT$m)
Month
Sales
M/M
Y/Y
YTD
Y/Y
Mar-18
147
(6.5%)
(16%)
476
12%
Feb-18
158
(8%)
59.6%
329
31.7%
Jan-18
171
9.5%
13.5%
171
13.5%
Dec-17
156
9.7%
62.2%
1,795
1.8%
Nov-17
143
(17.7%)
3.2%
1,639
(1.7%)
Oct-17
173
12.6%
28.8%
1,496
(2.1%)
Sep-17
154
5.4%
17.5%
1,323
(5.1%)
Aug-17
146
(18.4%)
19.3%
1,169
(7.4%)
Jul-17
179
16.7%
19.1%
1,024
(10.3%)
Jun-17
153
17.6%
(4.5%)
845
(14.8%)
May-17
130
(4.6%)
(21.7%)
692
(16.7%)
Apr-17
136
(22.2%)
(25.2%)
561
(15.5%)
Mar-17
175
77.6%
(6.2%)
425
(11.8%)
*Figures are consolidated
Source: TSE, compiled by Digitimes, April 2018Apex: Consolidated revenues, 4Q16 - 4Q17 (NT$m)
Quarter
Sales
Q/Q
Y/Y
YTD
Y/Y
4Q-17
472
(1.3%)
27.9%
1,795
1.8%
3Q-17
478
14%
18.7%
1,323
(5.1%)
2Q-17
420
(1.2%)
(17.5%)
845
(14.8%)
1Q-17
425
15.2%
(11.8%)
425
(11.8%)
4Q-16
369
(8.5%)
(23.1%)
1,763
(4.6%)
*Figures are consolidated
Source: TSE, compiled by Digitimes, April 2018Latest balance sheet and income statementApex: Consolidated balance sheet, 4Q16 - 4Q17 (NT$k)
Item
4Q-2017
3Q-2017
2Q-2017
1Q-2017
4Q-2016
Current assets
1,598,533
1,576,999
1,632,388
1,647,085
1,602,788
Intangible assets
294,089
304,638
314,386
25,010
25,854
Non-current assets
1,101,248
1,124,705
1,143,758
880,663
897,998
Assets
2,699,781
2,701,704
2,776,146
2,527,748
2,500,786
Current liabilities
1,018,272
1,062,660
818,230
482,436
414,574
Non-current liabilities
16,642
17,492
355,661
354,649
353,912
Liabilities
1,034,914
1,080,152
1,173,891
837,085
768,486
Stockholders' equity
1,664,867
1,621,552
1,602,255
1,690,663
1,732,300
*Figures are consolidated
Source: TSE, compiled by Digitimes, April 2018Apex: Consolidated income statement, 4Q16 - 4Q17 (NT$k)
Item
4Q-2017
3Q-2017
2Q-2017
1Q-2017
4Q-2016
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
Gross sales
478,449
419,801
424,990
Operating revenue
472,060
98.7%
478,449
100%
419,801
100%
424,990
100%
368,972
78.2%
Gross profit (loss) from operations
163,763
34.2%
102,951
21.5%
89,252
21.3%
75,548
17.8%
89,255
18.9%
Operating expenses
84,407
17.6%
77,552
16.2%
47,662
11.4%
60,894
14.3%
56,217
11.9%
Operating income (loss)
79,356
16.6%
25,399
5.3%
41,590
9.9%
14,654
3.4%
33,038
7%
Non-operating expenses and losses
-18,114
-3.8%
3,629
0.8%
19,106
4.6%
-53,646
-12.6%
-144,637
-30.6%
Income from continuing operations before income tax
61,242
12.8%
29,028
6.1%
60,696
14.5%
-38,992
-9.2%
-111,599
-23.6%
Net income (loss)
43,611
9.1%
20,501
4.3%
57,277
13.6%
-38,992
-9.2%
-130,469
-27.6%
Diluted earnings per share (NT$)
0.4
0.2
0
0
*Figures are consolidated
Source: TSE, compiled by Digitimes, April 2018 - Apex Biotechnology full profile